newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Tablets USP 200 mg

17th April, 2025, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP, 200 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. Carbamazepine Tablets USP, 200 mg are indicated for use as an anticonvulsant drug. It is also indicated in the treatment of the pain associated with true trigeminal neuralgia. Refer label for a detailed indication.

Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA.

Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA.

Related posts

Healthcare Must Transform, We Have a Responsibility to Mitigate Environmental Impact,” Asserts Dr. Dharminder Nagar Upon Winning Global Health Leader Award at the 10th IHW Summit

Newsmantra

Alembic Pharmaceuticals announces USFDA Tentative Approval for Bosutinib Tablets, 100 mg and 500 mg.

Newsmantra

Burnett Homeopathy Pvt. Ltd. Creates History with World Homoeopathy Summit 3 in Germany

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More